|Not for distribution to United States newswire services or for release, publication, distribution or
dissemination, directly or indirectly, in whole or in part, in or into the United States.
VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE:PULL)(OTC:PRXTF) (“Pure” or the “Company”) is pleased to announce that it has received approval from the Canadian Securities Exchange (the “CSE”) to list, as a supplemental listing on the CSE, a total of 8,447,739 common share purchase warrants (the “Warrants”) of the Company as a single class. The Warrants are being issued on conversion of 16,895,451 special warrants of the Company (the “Special Warrants”) as announced in the Company’s press releases on January 5, 2021 and January 21, 2021. The Warrants are expected to commence trading on the CSE under the symbol “PULL.WT” at the open of the market on March 10, 2021.
The Warrants are governed by a warrant indenture agreement between Pure and AST Trust Company (Canada) (the “Indenture”). In accordance with, and subject to the terms and conditions of, the Indenture, each Warrant will entitle the holder thereof to acquire one common share of the Company (each, a “Warrant Share”) upon payment of the exercise price of $0.65 per Warrant Share prior to March 10, 2023.
The Warrants were qualified pursuant to a prospectus supplement filed on March 8, 2021 with the securities commissions in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia and Prince Edward Island, as disclosed in the Company’s press release on March 8, 2021.
About the Company
Pure Extracts Technologies Corp. (CSE:PULL)(OTC:PRXTF) holds a Standard Processing License under the Cannabis Act granted by Health Canada on September 25, 2020 to Pure Extracts Manufacturing Corp., the Company’s wholly-owned subsidiary. The Company is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils. Additionally, the Company is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. The Company has a fully built CO2 extraction facility built to European Union GMP standards, and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal.
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts are forward-looking statements. Although the Company believes the expectations expressed in its forward-looking statements are based on reasonable assumptions, such statements should not be in any way construed as guarantees of the Company’s future performance. Although the Company believes the expectations expressed in its forward-looking statements are based on reasonable assumptions, such statements should not be in any way construed as guarantees. For more information on the Company, Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.